2019-nCoV is the third consecutive coronavirus spread during the last 2 decades, but this time, unlike the previous two occasions, has achieved a pandemic proportion threatening widespread loss of human lives and a massive setback to the global economy. The situation warrants drastic measures in terms of preventing the spread of the virus and treating the virus-infected patients. The development of a new vaccine is a time-intensive option. Although efforts are underway to find possible pharmacological options, e.g., chloroquine, hydroxychloroquine, existing antiviral agents, etc., in the meanwhile we may work on the combinatorial interventional approach of combining drug therapy with passive immune therapy. It would be prudent to use a convalescent serum therapy approach with the serum from COVID-19 patients who have recovered from the infection.
References
[1]
https://www.worldometers.info/coronavirus
[2]
Lu, H. (2020) Drug Treatment Options for the 2019—New Coronavirus (2019-nCoV). BioScience Trends, 14, 69-71. https://doi.org/10.5582/bst.2020.01020
[3]
Dong, L., Hu, S. and Gao, J. (2020) Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19). Drug Discoveries & Therapeutics, 14, 58-60. https://doi.org/10.5582/ddt.2020.01012
[4]
Gao, J., Tian, Z. and Yang, X. (2020) Breakthrough: Chloroquine Phosphate Has Shown Apparent Efficacy in Treatment of COVID-19 Associated Pneumonia in Clinical Studies. BioScience Trends, 14, 72-73. https://doi.org/10.5582/bst.2020.01047
[5]
Warhurst, D.C., Steele, J.C., Adagu, I.S., Craig, J.C. and Cullander, C. (2003) Hydroxychloroquine Is Much Less Active than Chloroquine against Chloroquine-Resistant Plasmodium falciparum, in Agreement with Its Physicochemical Properties. Journal of Antimicrobial Chemotherapy, 52, 188-193. https://doi.org/10.1093/jac/dkg319
[6]
Keyaerts, E., Vijgen, L., Maes, P., Neyts, J. and Van Ranst, M. (2004) In Vitro Inhibition of Severe Acute Respiratory Syndrome Coronavirus by Chloroquine. Biochemical and Biophysical Research Communications, 323, 264-268. https://doi.org/10.1016/j.bbrc.2004.08.085
[7]
Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., et al. (2020) Hydroxychloroquine, a Less Toxic Derivative of Chloroquine, Is Effective in Inhibiting SARS-CoV-2 Infection in Vitro. Cell Discovery, 6, 16. https://doi.org/10.1038/s41421-020-0156-0
[8]
Gautretab, P., Lagierac, J.-C., Parolaab, P., Hoang, V.-T., Meddeba, L., Mailhea, M., et al. (2020) Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial. International Journal of Antimicrobial Agents.
[9]
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., et al. (2020) Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in Vitro. Cell Research, 30, 269-271. https://doi.org/10.1038/s41422-020-0282-0
Andersen, K.G., Rambaut, A., Lipkin, W.I., Holmes, E.C. and Garry, R.F. (2020) The Proximal Origin of SARS-CoV-2. Nature Medicine. https://doi.org/10.1038/s41591-020-0820-9
[12]
Ji, J.S. (2020) Origins of MERS-CoV, and Lessons for 2019-nCoV. The Lancet, 4, e93. https://doi.org/10.1016/S2542-5196(20)30032-2
[13]
Marcotte, H. and Hammarström, L. (2015) Passive Immunization: Toward Magic Bullets. In: Mestecky, J., Strober, W., Russell, M., Cheroutre, H., Lambrecht, N.B. and Kelsall, B., Eds., Mucosal Immunology, 4th Edition, Elsevier Science, Amsterdam, Chapter 71, 1403-1433.
[14]
Cai, H.H. (2018) Therapeutic Monoclonal Antibodies Approved by FDA in 2017. MOJ Immunology, 6, 82-84. https://doi.org/10.15406/moji.2018.06.00198
[15]
Özen, M., Gündüz, M. and Haider, H.Kh. (2020) Chimeric Antigen Receptor (CAR) T-Cells as a Therapeutic Modality. In: Haider, H.Kh., Ed., Stem Cells: From Hype to Hope, WSP Company, Singapore, Chapter 8, 211-236. https://doi.org/10.1142/9789811205538_0008
[16]
Law, P.L. (2020) System Engineering of Emergent Serum Therapy to Combat COVID-19 and Other Pathogenic Pandemics. OJRM, 9, 8-14. https://doi.org/10.4236/ojrm.2020.91002
